<DOC>
	<DOC>NCT00189501</DOC>
	<brief_summary>Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters</brief_summary>
	<brief_title>A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>3 month history of Stage 4 or Stage 5 CKD A PTH value within 3 months of enrollment If relevant, completion of Sensipar® study prior to enrolling in Registry Exclusion Criteria: Females who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Chronic Kidney Disease, CKD,</keyword>
	<keyword>Secondary Hyperparathyroidism, HPT</keyword>
</DOC>